RxDoctor Payments Data

Srividya Venkataraman, MD

Family Medicine · Long Beach, CANPI 1063522217

Payments from drug & device makers

$697in general payments, 2019–2025

Across 26 payments — averaging $26.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$223
  • Sanofi-aventis U.S. LLC$166
  • Novo Nordisk$100
  • Abbott$82
  • Intra-sana Laboratories$32
  • Lilly USA, LLC$22
  • plus $72 from 4 others

What the payments were for

  • Speaking & faculty fees$15022%
  • Food & beverage$54778%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$697 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$154,396
Medicare patients
172
Services billed
1,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$72,935
JardianceEmpagliflozin38$60,173
OzempicSemaglutide27$54,670
JanuviaSitagliptin Phosphate52$47,657
ProliaDenosumab21$34,542
FarxigaDapagliflozin Propanediol18$27,954
XareltoRivaroxaban16$25,780
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$20,909
TrulicityDulaglutide11$20,160
JanumetSitagliptin Phos/Metformin Hcl12$13,450
MyrbetriqMirabegron13$13,450
Tresiba Flextouch U-200Insulin Degludec11$10,020
LinzessLinaclotide16$9,896
Wixela InhubFluticasone Propion/Salmeterol20$7,203
SynjardyEmpagliflozin/Metformin Hcl12$6,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$17$66,72950 claims
Novo NordiskOzempic$100$54,67027 claims
AmgenProlia$18$34,54221 claims
AstraZenecaFarxiga$223$27,95418 claims
Lilly USA, LLCTrulicity$22$20,16011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →